Axicabtagene ciloleucel

Definition

Axicabtagene ciloleucel is a type of CAR T-cell therapy specifically designed to treat certain types of large B-cell lymphoma, which is a form of non-Hodgkin lymphoma. This innovative treatment involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that targets the CD19 protein found on the surface of cancerous B cells. By harnessing the body’s immune system, this therapy represents a significant advancement in cancer chemotherapy.

5 Must Know Facts For Your Next Test

1. Axicabtagene ciloleucel is marketed under the brand name Yescarta and was approved by the FDA in 2017 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
2. The treatment involves collecting a patient’s T cells, modifying them in a lab to express CARs, and then infusing them back into the patient to help fight the cancer.
3. Patients receiving axicabtagene ciloleucel can experience side effects such as cytokine release syndrome (CRS) and neurological toxicities, which require careful monitoring.
4. Axicabtagene ciloleucel has shown high response rates in clinical trials, with many patients experiencing significant reductions in tumor size or complete remission.
5. As an example of personalized medicine, axicabtagene ciloleucel illustrates how advancements in genetic engineering and immunotherapy are revolutionizing cancer treatment.

Review Questions

• What are the mechanisms by which axicabtagene ciloleucel targets and eliminates cancer cells?
  • Axicabtagene ciloleucel works by genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that specifically target CD19 proteins on malignant B cells. When these modified T cells are reintroduced into the patient, they recognize and bind to CD19, leading to the activation of the T cells and prompting them to attack and kill the cancerous B cells. This targeted approach enhances the body's immune response against cancer while minimizing damage to normal cells.
• Discuss the potential side effects associated with axicabtagene ciloleucel and their implications for patient management.
  • Patients treated with axicabtagene ciloleucel may experience significant side effects, particularly cytokine release syndrome (CRS) and neurological symptoms. CRS occurs when there is a rapid release of cytokines into the bloodstream after T cell activation, leading to symptoms like fever, nausea, and severe inflammatory responses. Neurological toxicities can range from confusion to seizures. These side effects necessitate close monitoring and may require interventions such as corticosteroids or supportive care, which are critical for patient safety and successful outcomes.
• Evaluate how axicabtagene ciloleucel represents a shift in cancer treatment paradigms compared to traditional chemotherapy.
  • Axicabtagene ciloleucel exemplifies a significant shift from traditional chemotherapy towards more targeted and personalized cancer therapies. Unlike conventional chemotherapy, which indiscriminately targets rapidly dividing cells—affecting both cancerous and healthy tissues—axicabtagene ciloleucel specifically modifies T cells to target CD19 on malignant B cells, leading to potentially higher efficacy with fewer side effects. This advancement highlights the growing trend towards immunotherapy and personalized medicine in oncology, as treatments become more tailored to individual patients' unique tumor profiles and immune responses.

Related terms

CAR T-cell therapy: A form of immunotherapy where a patient's T cells are genetically engineered to attack cancer cells.

CD19: A protein expressed on the surface of B cells, including malignant B cells in certain lymphomas, making it a target for CAR T-cell therapies.

non-Hodgkin lymphoma: A group of blood cancers that includes any lymphoma except Hodgkin's lymphomas, characterized by the uncontrolled growth of lymphocytes.